Company intelligence / Profile preview

Yingkai Saiwei

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Innovo Therapeutics is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative small molecule drugs and targeted protein degradation (PROTAC) therapies. The company focuses on addressing unmet medical needs in oncology and autoimmune diseases through its proprietary drug discovery platforms. Its pipeline includes several candidates targeting key disease drivers, with lead programs currently in early-stage clinical trials. Innovo aims to leverage its expertise in medicinal chemistry and biology to deliver next-generation precision medicines.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Drug pipeline

2 assets

YK0901

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Yingkai Saiwei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yingkai Saiwei.

Explore the full profile